Q2 FY26 results: consolidated net profit up sharply YoY

Pat Growth 25pctExceptional ItemResults RestatedRelated Party TransactionsResults View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹331.00

prior close

₹325.50

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-2.4%+0.4% vs market

Pharmaceuticals peers, median of 156sector-2.0%-0.0% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

+0.1

15m

-0.1

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0-2.4+0.4-2.0-0.0

Next day

+1.2-0.4+1.7-1.4+2.6

-0.3-1.1+0.7-1.4+1.1

-0.3-0.6+0.3-1.0+0.7

-0.9-0.4-0.5-0.8-0.1

-2.4+0.1-2.5-0.5-1.9

-2.0-1.4-0.6-2.1+0.1

15d

-4.7-1.0-3.8-2.0-2.7

-8.0-0.8-7.2-0.8-7.2

+0.6-0.9+1.5-5.2+5.8

+1.4-11.3+12.7-11.8+13.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare reported H1 FY26 (ended Sep 30, 2025) consolidated revenue of 691 crore rupees, up 8.7% YoY. Consolidated net profit attributable to owners surged to 91 crore from 32 crore last year, boosted by a tax reversal from the merger of subsidiary INM Technologies. Standalone total income dipped 5.7% to 262 crore. Consolidated EPS was 4.65 versus 1.65. Company allotted 1:1 bonus shares on October 7.

Likely market impact

Strong consolidated earnings growth on tax boost and lower exceptional items; bonus shares already issued, so past EPS now restated.